Bumrungrad Hospital Public Company Limited (BUGDF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bumrungrad Hospital Public Company Limited (BUGDF) with AI Score 46/100 (Weak). Bumrungrad Hospital Public Company Limited operates a leading medical center in Thailand, providing a wide range of diagnostic, therapeutic, and intensive care services to both domestic and international patients. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Bumrungrad Hospital Public Company Limited (BUGDF) Healthcare & Pipeline Overview
Bumrungrad Hospital Public Company Limited, based in Thailand, operates a comprehensive medical center offering diverse healthcare services, including specialized clinics and diagnostic facilities. With a focus on international patients and a high profit margin of 29.8%, the company distinguishes itself through its commitment to quality care and a wide range of medical specialties.
Investment Thesis
Bumrungrad Hospital Public Company Limited presents a notable research candidate due to its strong market position, high profitability, and growth potential in the healthcare sector. The company's profit margin of 29.8% and gross margin of 51.8% indicate efficient operations and pricing power. The dividend yield of 2.82% offers an attractive income stream for investors. Growth catalysts include expanding medical tourism, increasing demand for specialized medical services, and strategic investments in new technologies and facilities. However, potential risks include competition from other healthcare providers, regulatory changes, and economic fluctuations affecting patient volumes. Bumrungrad's beta of -0.07 suggests low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $3.78 billion reflects Bumrungrad's significant presence in the healthcare industry.
- P/E ratio of 18.75 indicates a reasonable valuation compared to its earnings.
- Profit margin of 29.8% demonstrates strong profitability and efficient cost management.
- Gross margin of 51.8% highlights the company's ability to generate revenue from its services.
- Dividend yield of 2.82% provides an attractive income stream for investors.
Competitors & Peers
Strengths
- Strong brand reputation and recognition.
- Comprehensive range of medical services.
- Strategic location for medical tourism.
- High profit margin and financial performance.
Weaknesses
- Dependence on international patients.
- Exposure to currency fluctuations.
- Competition from other healthcare providers.
- Regulatory risks in the healthcare industry.
Catalysts
- Ongoing: Expansion of medical tourism services targeting new international markets.
- Ongoing: Development of specialized medical centers focused on high-demand areas like oncology and cardiology.
- Ongoing: Investment in digital health technologies to improve patient experience and operational efficiency.
- Upcoming: Potential strategic partnerships or acquisitions to expand geographic reach and service offerings.
- Ongoing: Focus on preventive healthcare services to capitalize on the growing demand for wellness programs.
Risks
- Potential: Economic downturns could reduce patient volumes and impact revenue.
- Potential: Political instability in Thailand could disrupt operations and deter medical tourists.
- Potential: Outbreaks of infectious diseases could strain resources and reduce patient confidence.
- Ongoing: Competition from other healthcare providers in Thailand and internationally.
- Ongoing: Changes in healthcare regulations could increase compliance costs and affect profitability.
Growth Opportunities
- Expansion of Medical Tourism: Bumrungrad has a significant opportunity to further expand its medical tourism business by targeting new markets and offering specialized packages for international patients. The global medical tourism market is projected to reach $272.7 billion by 2027, growing at a CAGR of 12.8% from 2020. Bumrungrad can leverage its reputation for quality and its strategic location in Bangkok to attract more patients from Asia, the Middle East, and other regions. Timeline: Ongoing.
- Development of Specialized Medical Centers: Bumrungrad can enhance its service offerings and attract more patients by developing specialized medical centers focused on specific areas such as oncology, cardiology, and orthopedics. These centers can offer advanced diagnostic and treatment options, attracting patients seeking specialized care. The market for specialized medical services is growing rapidly, driven by increasing prevalence of chronic diseases and advancements in medical technology. Timeline: Ongoing.
- Investment in Digital Health Technologies: Bumrungrad can improve patient experience and operational efficiency by investing in digital health technologies such as telemedicine, remote monitoring, and electronic health records. These technologies can enable the company to provide more convenient and accessible healthcare services, attract younger patients, and reduce costs. The digital health market is expected to reach $660 billion by 2025, growing at a CAGR of 28.5% from 2020. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Bumrungrad can expand its geographic reach and service offerings through strategic partnerships and acquisitions. The company can partner with other healthcare providers, insurance companies, and technology companies to offer integrated healthcare solutions and reach new markets. Acquisitions can enable Bumrungrad to acquire new technologies, expand its service offerings, and increase its market share. Timeline: Ongoing.
- Focus on Preventive Healthcare: Bumrungrad can capitalize on the growing demand for preventive healthcare services by offering health screening programs, wellness programs, and lifestyle coaching. These services can help patients prevent chronic diseases, improve their overall health, and reduce healthcare costs. The preventive healthcare market is expected to reach $432.3 billion by 2027, growing at a CAGR of 10.2% from 2020. Timeline: Ongoing.
Opportunities
- Expansion of medical tourism business.
- Development of specialized medical centers.
- Investment in digital health technologies.
- Strategic partnerships and acquisitions.
Threats
- Economic downturns affecting patient volumes.
- Political instability in Thailand.
- Outbreaks of infectious diseases.
- Changes in healthcare regulations.
Competitive Advantages
- Strong brand reputation and recognition in the healthcare industry.
- Strategic location in Bangkok, a major hub for medical tourism.
- Comprehensive range of medical services and specialties.
- Focus on international patients and high-quality care.
- Advanced medical technologies and facilities.
About BUGDF
Founded in 1980 and headquartered in Bangkok, Thailand, Bumrungrad Hospital Public Company Limited has evolved into a leading healthcare provider in Southeast Asia. The company operates a 580-bed medical center with approximately 56 clinics and centers, offering a comprehensive range of medical services. These include diagnostic, therapeutic, and intensive care facilities, catering to both local and international patients. Bumrungrad's outpatient clinics and centers cover a wide spectrum of specialties, such as allergy, cardiology, oncology, orthopedics, and women's health. The hospital is also involved in real estate asset holding, clinical research services, and the distribution of pharmaceutical and medical goods through specialized stores. Bumrungrad has established itself as a premier destination for medical tourism, attracting patients from around the world seeking high-quality healthcare services. The company is committed to continuous improvement and innovation, investing in advanced medical technologies and fostering a culture of excellence among its healthcare professionals. Its focus on patient-centric care and international standards has contributed to its strong reputation and financial performance.
What They Do
- Operates a 580-bed medical center in Bangkok, Thailand.
- Provides diagnostic, therapeutic, and intensive care facilities.
- Offers a wide range of outpatient clinics and centers covering various medical specialties.
- Caters to both local and international patients.
- Engages in real estate asset holding activities.
- Provides clinical research services.
- Distributes pharmaceutical and medical goods through specialized stores.
- Operates a personnel development and training center for healthcare services.
Business Model
- Generates revenue from providing medical services to patients.
- Attracts international patients seeking high-quality and affordable healthcare.
- Offers a comprehensive range of medical specialties and services.
- Invests in advanced medical technologies and facilities.
- Focuses on patient-centric care and international standards.
Industry Context
Bumrungrad Hospital Public Company Limited operates within the growing healthcare industry, driven by factors such as aging populations, increasing prevalence of chronic diseases, and rising healthcare expenditure. The medical tourism market is a significant growth driver, with patients seeking high-quality and affordable healthcare services in countries like Thailand. The competitive landscape includes other private hospitals and medical centers, both domestic and international. Bumrungrad differentiates itself through its focus on international patients, comprehensive range of services, and commitment to quality and innovation. The healthcare industry is subject to regulatory oversight and technological advancements, requiring companies to adapt and invest in new capabilities.
Key Customers
- Local patients in Thailand seeking medical care.
- International patients seeking medical tourism services.
- Insurance companies and healthcare providers.
- Corporate clients seeking employee health benefits.
- Patients seeking specialized medical treatments and procedures.
Financials
Chart & Info
Bumrungrad Hospital Public Company Limited (BUGDF) stock price: Price data unavailable
Latest News
No recent news available for BUGDF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BUGDF.
Price Targets
Wall Street price target analysis for BUGDF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BUGDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Artirat Charukitpipat
CEO
Artirat Charukitpipat serves as the Chief Executive Officer of Bumrungrad Hospital Public Company Limited. Her career reflects a deep understanding of the healthcare industry and a commitment to excellence in patient care. She has held various leadership positions within Bumrungrad, contributing to the hospital's strategic growth and operational efficiency. Her expertise spans across hospital management, business development, and international healthcare services. She is known for her focus on innovation and leveraging technology to enhance the patient experience.
Track Record: Under Artirat Charukitpipat's leadership, Bumrungrad Hospital has continued to strengthen its position as a leading healthcare provider in Southeast Asia. She has overseen the implementation of key initiatives aimed at improving patient outcomes, enhancing operational efficiency, and expanding the hospital's international reach. Her strategic decisions have contributed to the company's strong financial performance and its ability to adapt to the evolving healthcare landscape.
BUGDF OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure and may not meet minimum listing requirements. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in higher risks for investors. This tier includes companies that are defunct, in bankruptcy, or unwilling to provide current financial information. Investing in OTC Other stocks requires significant due diligence and an understanding of the associated risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in BUGDF.
- Low liquidity can make it difficult to buy or sell shares at desired prices.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- Lack of regulatory oversight compared to major exchanges.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review any available news articles or press releases about the company.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Check for any regulatory actions or legal proceedings involving the company.
- Bumrungrad Hospital Public Company Limited is a well-established healthcare provider in Thailand.
- The company has a long operating history, founded in 1980.
- Bumrungrad is a publicly traded company, subject to some level of scrutiny.
- The company has a significant market capitalization, suggesting a substantial business.
- Bumrungrad has a dividend yield, indicating a commitment to returning value to shareholders.
Common Questions About BUGDF
What does Bumrungrad Hospital Public Company Limited do?
Bumrungrad Hospital Public Company Limited operates a leading private hospital in Bangkok, Thailand, providing a comprehensive range of medical services to both local and international patients. The hospital offers diagnostic, therapeutic, and intensive care facilities, with specialized clinics and centers covering various medical specialties such as cardiology, oncology, orthopedics, and neurology. Bumrungrad focuses on attracting medical tourists by providing high-quality care, advanced medical technologies, and a patient-centric approach, making it a prominent player in the medical tourism industry.
What do analysts say about BUGDF stock?
Analyst coverage of BUGDF stock is limited due to its OTC listing. However, considering its strong market position in Thailand's healthcare sector, its focus on medical tourism, and its consistent profitability, analysts generally view Bumrungrad Hospital Public Company Limited as a stable and reliable company. Key valuation metrics such as P/E ratio and dividend yield suggest a reasonable valuation. Growth considerations include the expansion of medical tourism, strategic investments in new technologies, and the development of specialized medical centers. No buy/sell recommendations are being made.
What are the main risks for BUGDF?
The main risks for Bumrungrad Hospital Public Company Limited include economic downturns that could reduce patient volumes, political instability in Thailand that could deter medical tourists, and outbreaks of infectious diseases that could strain resources and reduce patient confidence. Competition from other healthcare providers in Thailand and internationally also poses a risk. Additionally, changes in healthcare regulations could increase compliance costs and affect profitability. As an OTC stock, there are also risks associated with limited liquidity and financial disclosure.
What are the key factors to evaluate for BUGDF?
Bumrungrad Hospital Public Company Limited (BUGDF) currently holds an AI score of 46/100, indicating low score. Key strength: Strong brand reputation and recognition.. Primary risk to monitor: Potential: Economic downturns could reduce patient volumes and impact revenue.. This is not financial advice.
How frequently does BUGDF data refresh on this page?
BUGDF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BUGDF's recent stock price performance?
Recent price movement in Bumrungrad Hospital Public Company Limited (BUGDF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand reputation and recognition.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BUGDF overvalued or undervalued right now?
Determining whether Bumrungrad Hospital Public Company Limited (BUGDF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BUGDF?
Before investing in Bumrungrad Hospital Public Company Limited (BUGDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data and market information are based on available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- This analysis is for informational purposes only and does not constitute investment advice.